JNJ-40418677

JNJ-40418677 is an orally active modulator of γ-secretase, can cross the blood-brain barrier. JNJ-40418677 inhibits Aβ42 and NS2B-NS3 protease, with IC50s of 200 nM and 3.9 μM, respectively. JNJ-40418677 displays good biological tolerance, can be use for Alzheimer’s disease research[1][2][3].

Product Specifications

CAS Number

[1146594-87-7]

UNSPSC

12352005

Hazard Statement

H300

Target

Amyloid-β; γ-secretase

Type

Reference compound

Related Pathways

Neuronal Signaling; Stem Cell/Wnt

Applications

Neuroscience-Neurodegeneration

Field of Research

Neurological Disease

Assay Protocol

https://www.medchemexpress.com/jnj-40418677.html

Purity

99.48

Solubility

DMSO : 100 mg/mL (ultrasonic)

Smiles

CC(C)C[C@@H](C1=CC(C2=CC=C(C=C2)C(F)(F)F)=CC(C3=CC=C(C=C3)C(F)(F)F)=C1)C(O)=O

Molecular Formula

C26H22F6O2

Molecular Weight

480.44

Precautions

H300

References & Citations

[1]Van Broeck B, et al. Chronic treatment with a novel γ-secretase modulator, JNJ-40418677, inhibits amyloid plaque formation in a mouse model of Alzheimer's disease. Br J Pharmacol. 2011 May;163 (2) :375-89. |[2]Harrie J.M. Gijsen, et al. Chapter Five - Secretase Inhibitors and Modulators as a Disease-Modifying Approach Against Alzheimer's Disease. Annu Rep Med Chem. 2012. 47:55-69.|[3]Samrat SK, et al. Antiviral Agents against Flavivirus Protease: Prospect and Future Direction. Pathogens. 2022 Feb 25;11 (3) :293.